All In Biotech

Drug Trial Radar · NCT06537817

Study to Evaluate HT-4253 in Healthy Subjects

A Phase 1, First-in-Human, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses (SAD) and Multiple Ascending Doses (MAD) of Oral HT-4253 in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jun 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

Sep 17, 2024

Primary completion

May 12, 2025

Study completion May 12, 2025

Sponsor

Lead sponsor
Halia Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Aug 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the safety and tolerability of HT-4253 when administered as single oral doses and multiple oral doses at escalating dose levels in healthy volunteer subjects. The secondary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of HT-4253.

Conditions

  • Normal Healthy Subjects

Interventions

  • HT-4253Drug

    HT-4253 Single or Multiple doses administered orally as a tablet

  • PlaceboDrug

    Placebo to match HT-4253 Single or Multiple doses administered orally as a tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the safety and tolerability of single and multiple ascending doses of oral HT-4253 in healthy adultsTime frame: up to 6 weeks
  2. To evaluate the safety and tolerability of single and multiple ascending doses of oral HT-4253 in healthy adultsTime frame: up to 6 weeks
  3. To evaluate the safety and tolerability of single and multiple ascending doses of oral HT-4253 in healthy adultsTime frame: up to 6 weeks
  4. To evaluate the safety and tolerability of single and multiple ascendingTime frame: up to 6 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.